A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
Condition: Metastatic Breast Cancer Interventions: Drug: Pyrotinib; Drug: Treatment of physician's choice; Drug: vinorelbine Sponsors: Sun Yat-sen University; Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials